Skip to main content
. 2024 Jun 1;14(9):3509–3525. doi: 10.7150/thno.96946

Figure 5.

Figure 5

Delivery of tsRNA1599 has no obvious retinal toxicity in vivo. (A) Diagram illustrating the experimental procedure for assessing the effects of altered tsRNA-1599 levels on the retinal toxicity for 7 days. (B) IB4 staining of retinal flat-mounts injected with scramble (Scr) agomir (20 μM, 2 μL), tsRNA-1599 agomir (20 μM, 2 μL), Scr antagomir (20 μM, 2 μL), tsRNA-1599 antagomir (20 μM, 2 μL), or PBS for 7 days (Scale bar, 500 μm). Quantification of vascular junction and length were shown (n = 5). (C) Immunofluorescence staining of the retinas injected with Scr agomir (20 μM, 2 μL), tsRNA-1599 agomir (20 μM, 2 μL), Scr antagomir (20 μM, 2 μL), tsRNA-1599 antagomir (20 μM, 2 μL), or PBS for 7 days with NeuN and Rhodopsin (Scale bar, 50 μm). Quantification results and representative images of NeuN and Rhodopsin staining were shown (n = 5). (D) The retinas were administered with Scr agomir (20 μM, 2 μL), tsRNA-1599 agomir (20 μM, 2 μL), Scr antagomir (20 μM, 2 μL), tsRNA-1599 antagomir (20 μM, 2 μL), or PBS for 7 days (Scale bar, 20 μm). Quantitative results and representative images of RBPMS staining are depicted (n = 5). The displayed images were captured at a location halfway between the center and the periphery of retina. (E) TUNEL staining of the retinas injected with Scr agomir (20 μM, 2 μL), tsRNA-1599 agomir (20 μM, 2 μL), Scr antagomir (20 μM, 2 μL), tsRNA-1599 antagomir (20 μM, 2 μL), or PBS for 7 days (Scale bar, 50 μm). “ns” represents no statistical significance; One-way ANOVA followed by Bonferroni's post hoc test.